Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The U.S. Federal Trade Commission gave the green light to the $63 billion merger of AbbVie and Allergan. That leaves one last hurdle for the two companies, approval from the Irish High Court.
Alexion said the acquisition of Portola will bolster its commercial portfolio and create long-term value for its shareholders.
Shares of New York-based Stemline Therapeutics skyrocketed more than 153% in premarket trading after Italy’s Menarini Group announced a $667 million acquisition of the oncology-focused company.
Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC
Four months after raising $30 million in a Series C financing round, Watertown, Mass.-based Lyra Therapeutics raised an additional $56 million in its initial public offering.
The deal is expected to close in the second half of 2020. Once finalized, the combined company will run under the name Adicet Bio and is expected to trade on the Nasdaq Global Market under a new ticker symbol, which hasn’t been announced yet.
Company enters next development phase with management expansion and implementation of a Strategic and Scientific Advisory Board
Heidelberg Pharma AG announces that it has successfully raised approximately EUR 14.4 million in gross proceeds through a private placement via an accelerated book building transaction.
FoRx Therapeutics AG, the biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways, announced the closing of a EUR 10 million seed financing led by M Ventures, Novartis Venture Fund and Omega Funds.
Despite booming commercial interest in plant-based and cultivated meat, funding for academic research lags behind, and the industries lack the open-access data required to overcome technical hurdles and scale up to become a viable part of the global food system.